- Home
- ARMN vs DCTH Comparison
ARMN vs DCTH Comparison
Compare ARMN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- DCTH
- Stock Information
- Founded
- ARMN 1992
- DCTH 1988
- Country
- ARMN Canada
- DCTH United States
- Employees
- ARMN N/A
- DCTH N/A
- Industry
- ARMN
- DCTH Medical/Dental Instruments
- Sector
- ARMN
- DCTH Health Care
- Exchange
- ARMN Nasdaq
- DCTH Nasdaq
- Market Cap
- ARMN 769.7M
- DCTH 630.4M
- IPO Year
- ARMN N/A
- DCTH N/A
- Fundamental
- Price
- ARMN $6.54
- DCTH $16.21
- Analyst Decision
- ARMN
- DCTH Strong Buy
- Analyst Count
- ARMN 0
- DCTH 4
- Target Price
- ARMN N/A
- DCTH $24.00
- AVG Volume (30 Days)
- ARMN 1.2M
- DCTH 610.5K
- Earning Date
- ARMN 05-07-2025
- DCTH 05-08-2025
- Dividend Yield
- ARMN N/A
- DCTH N/A
- EPS Growth
- ARMN 28.55
- DCTH N/A
- EPS
- ARMN 0.15
- DCTH N/A
- Revenue
- ARMN $560,512,000.00
- DCTH $53,850,000.00
- Revenue This Year
- ARMN $49.45
- DCTH $141.47
- Revenue Next Year
- ARMN N/A
- DCTH $49.31
- P/E Ratio
- ARMN $41.94
- DCTH N/A
- Revenue Growth
- ARMN 22.28
- DCTH 1068.87
- 52 Week Low
- ARMN $3.29
- DCTH $6.33
- 52 Week High
- ARMN $6.59
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ARMN 67.43
- DCTH 58.15
- Support Level
- ARMN $6.12
- DCTH $16.02
- Resistance Level
- ARMN $6.59
- DCTH $17.29
- Average True Range (ATR)
- ARMN 0.21
- DCTH 0.99
- MACD
- ARMN 0.03
- DCTH -0.03
- Stochastic Oscillator
- ARMN 95.26
- DCTH 49.63
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.